Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female patients of at least 18 years old~* HVPG \> 12 mm Hg in fasting state on Day 1~* Free of any other condition (except liver failure) that may alter absorption, distribution, or elimination of drugs~Exclusion Criteria:~* Oesophageal bleeding in the previous 30 days~* Known intolerance to ursodeoxycholic acid or nitrates~* Liver cancer or liver metastasis from another cancer~* Portal hypertension secondary to venous thrombosis~* Presence of Transjugular Intrahepatic Portosystemic Shunt (TIPS)~* Severe liver failure (Child-Pugh C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NCX-1000 (Type: EXPERIMENTAL): Experimental drug under evaluation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo powder

Based on this trial design, predict the completion outcome and termination type (if applicable).